Touyun Biotech details use of HK$14.99 million net proceeds from share subscription

PUBT · 4d ago
Touyun Biotech details use of HK$14.99 million net proceeds from share subscription
  • Touyun Biotech issued a clarification on use of proceeds for its new-share subscription under a general mandate.
  • Net proceeds expected at HK$14.99 million, targeted for full use by Dec. 31, 2026.
  • HK$7 million earmarked for a new production line at an indirect non-wholly-owned unit making high thermal conductivity materials.
  • Remaining funds allocated to settle payables and support working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Touyun Biotech Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309280), on August 31, 2026, and is solely responsible for the information contained therein.